0000905718-21-000760.txt : 20210607 0000905718-21-000760.hdr.sgml : 20210607 20210607085345 ACCESSION NUMBER: 0000905718-21-000760 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210603 FILED AS OF DATE: 20210607 DATE AS OF CHANGE: 20210607 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Muralidhar Bali CENTRAL INDEX KEY: 0001784138 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40315 FILM NUMBER: 21998379 MAIL ADDRESS: STREET 1: C/O EXICURE, INC. STREET 2: 8045 LAMON AVENUE, SUITE 410 CITY: SKOKIE STATE: IL ZIP: 60077 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Reneo Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001637715 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 472309515 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 230 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 283-0280 MAIL ADDRESS: STREET 1: 12230 EL CAMINO REAL STREET 2: SUITE 230 CITY: SAN DIEGO STATE: CA ZIP: 92130 4 1 reneo_fm4jun32021.xml X0306 4 2021-06-03 0 0001637715 Reneo Pharmaceuticals, Inc. RPHM 0001784138 Muralidhar Bali C/O RENEO PHARMACEUTICALS, INC. 12230 EL CAMINO REAL, SUITE 230 SAN DIEGO CA 92130 1 0 0 0 Common Stock 2021-06-03 4 P 0 12100 9.2515 A 1877375 I By Abingworth Bioventures 8 LP Common Stock 2021-06-04 4 P 0 257 9.4242 A 1877632 I By Abingworth Bioventures 8 LP The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.08 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.30 to $9.50 per share, inclusive. The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. The shares are held by Abingworth Bioventures 8 LP ("Abingworth 8"). Abingworth Bioventures 8 GP LP serves as the general partner of Abingworth 8. Abingworth General Partner 8 LLP, (together with Abingworth Bioventures 8 GP LP, the "General Partners"), serves as the general partner of Abingworth Bioventures 8 GP LP. Abingworth 8 (acting by its general partner Abingworth Bioventures 8 GP LP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP all investment and dispositive power over the securities held by Abingworth 8. The Reporting Person, a Director of the Issuer, is a member of an investment committee of Abingworth 8 which approves investment and voting decisions by majority vote and no individual member has the sole control or voting power over the securities held by Abingworth 8. Each of Abingworth 8, Abingworth LLP, the General Partners, the Reporting Person and each member of the Investment Committee disclaims beneficial ownership of the common stock held by Abingworth 8, except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that the Reporting Person or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. /s/ John Heard, as attorney-in-fact 2021-06-07